Last reviewed · How we verify
ACE Inhibitors and Diuretics
ACE inhibitors block angiotensin-converting enzyme to reduce angiotensin II production and lower blood pressure, while diuretics increase sodium and water excretion to reduce fluid volume and blood pressure.
ACE inhibitors block angiotensin-converting enzyme to reduce angiotensin II production and lower blood pressure, while diuretics increase sodium and water excretion to reduce blood volume and fluid overload. Used for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction.
At a glance
| Generic name | ACE Inhibitors and Diuretics |
|---|---|
| Sponsor | The University of Texas Health Science Center, Houston |
| Drug class | ACE inhibitor + diuretic combination |
| Target | Angiotensin-converting enzyme (ACE); various diuretic targets depending on class (e.g., loop of Henle, distal convoluted tubule) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
ACE inhibitors prevent the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby reducing peripheral vascular resistance and blood pressure. Diuretics work through different mechanisms (thiazide, loop, or potassium-sparing) to promote renal sodium and water excretion, decreasing circulating blood volume. The combination provides complementary antihypertensive effects and is commonly used in fixed-dose formulations for improved patient adherence.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Post-myocardial infarction
Common side effects
- Cough
- Dizziness
- Hyperkalemia (ACE inhibitor component)
- Hypokalemia (diuretic component)
- Fatigue
- Headache
- Angioedema (rare)
Key clinical trials
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- Venous Congestion And Cognitive Dysfunction After Cardiac Surgery
- Baroreflex Activation Therapy for Heart Failure (NA)
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
- Exercise Rehabilitation for Cardiorenal Syndrome in HFrEF Patients (NA)
- Colchicine Versus Placebo in Acute Myocarditis Patients (PHASE3)
- To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction. (PHASE3)
- OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: